Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial-Reference-Cited by-同舟云学术

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial

Published:2022-08 Issue:8 Volume:23 Page:1021-1030
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pagel John M,Soumerai Jacob D,Reddy Nishitha,Jagadeesh Deepa,Stathis Anastasios,Asch Adam,Salman Huda,Kenkre Vaishalee P,Iasonos Alexia,Llorin-Sangalang Judith,Li Joanne,Zelenetz Andrew D

Funder

MEI Pharma

Lymphoma Research Foundation

Memorial Sloan-Kettering Cancer Center

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia;Herman;Clin Cancer Res,2012

2. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia;Hoellenriegel;Blood,2011

3. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability;Lannutti;Blood,2011